Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: Results at 1 year

Digestive and Liver Disease

Volumn 42, Issue 6, 2010, Pages 432-435

  Cabriada, Jose L ^a   Ibargoyen, Nora ^a,b   Hernández, Anaiansi ^a   Bernal, Antonio ^a   Castiella, Agustín ^c  

^a HOSPITAL DE GALDAKAO   (Spain)

^b Basque Office for Health Technology Assessment   (Spain)

^c HOSPITAL DE MENDARO   (Spain)

Author keywords

Leukocytapheresis; Steroid dependent; Steroids free sustained remission; Ulcerative colitis

Indexed keywords

STEROID; GLUCOCORTICOID;

ADULT; APHERESIS; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; INTESTINE ENDOSCOPY; LEUKOCYTAPHERESIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT RESPONSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; COLONOSCOPY; COMPARATIVE STUDY; CONTROLLED STUDY; INTESTINE MUCOSA; LEUKAPHERESIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTESTINAL MUCOSA; LEUKAPHERESIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952746143     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.09.001     Document Type: Article

References (40)

1. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
2. Stange E.F., Travis S., Vermeire S., et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008, 2:1-23.
3. Travis S., Stange E.F., Lémann M., et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008, 2:24-62.
4. Bianchi Porro G., Cassinotti A., Ferrara E., et al. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007, 26:779-794.
5. Ardizzone S., Maconi G., Russo A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
6. Rutgeerts P., Sandborn W., Feagan B., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
7. McCarthy D.A., Rampton D.S., Liu Y.C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991, 86:489-493.
8. Tibble J.A., Sigthorson G., Bridger D. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119:15-22.
9. Kashiwagi N., Sugimura K., Koiwai H., et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002, 47:1334-1341.
10. Mitsuyama K., Suzuki A., Matsumoto S., et al. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 2005, 141:130-140.
11. Hanai H., Watanabe F., Yamada M., et al. Correlation of serum soluble TNF-α receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004, 99:1532-1538.
12. Takeda Y., Shiobara N., Saniabadi A.R., et al. Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and beta2 integrin. Inflamm Res 2004, 53:277-283.
13. Hanai H. Position of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006, 12:7568-7577.
14. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24:2-6.
15. Schroeder K., Tremaine W., Ilstrup D. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
16. Cabriada J.L., Bernal A., Hernández A., et al. Leukapheresis in remission induction and steroid withdrawal in steroid-dependent ulcerative colitis. Dial Traspl 2007, 28:47-55.
17. Bresci G., Parisi G., Mazzoni A., et al. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liv Dis 2007, 39:430-434.
18. Yamamoto T., Umegae S., Kitagawa T., et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective pilot study. Aliment Pharmacol Ther 2004, 20:783-792.
19. Kanke K., Nakano M., Hiraishi H., et al. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004, 36:811-817.
20. Yamamoto T., Saniabadi A.R., Maruyama Y., et al. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liv Dis 2007, 39:626-633.
21. Sands B., Sandborn W., Feagan B., et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008, 135:400-409.
22. Gisbert J.P., Gónzalez-Lama Y., Maté J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2006, 25:19-37.
23. García S., Gomollón F., Pérez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005, 28:607-614.
24. Ljung T., Thomsen O., Vatn M., et al. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007, 42:221-227.
25. Takemoto K., Kato J., Kuriyama M., et al. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liv Dis 2007, 39:422-429.
26. Cabriada J.L., Domènech E., Gomollón F., et al. Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease. Gastroenterol Hepatol 2006, 29:85-92.
27. Sawada K., Muto T., Shimoyama T., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003, 9:307-321.
28. Hanai H., Watanabe F., Yamada M., et al. Adsortive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004, 70:36-44.
29. Sawada K., Hiwatashi N., Munakata A., et al. A multicentre randomized controlled study of safety and efficacy of adsorptive granulocyte and monocyte apheresis in patients with active ulcerative colitis. Gastroenterology 2004, 126:A462.
30. Panés J., Aceituno M., Domènech E., et al. Leukocytapheresis in the treatment of inflammatory bowel disease. GH Continuada 2005, 4:227-232.
31. Naganuma M., Funakoshi S., Sakuraba A., et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004, 10:251-257.
32. Doménech E., Hinojosa J., Esteve-Comas M., et al. Granulocytapheresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004, 20:1347-1352.
33. Ricart E., Esteve M., Andreu M., et al. Evaluation of 5 versus 10 granulocytapharesis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007, 13:2193-2197.
34. D'Ovidio V., Aratari A., Viscido A., et al. Long term follow-up in ulcerative colitis patients underwent granulocyte-monocyte-apheresis for steroid dependency/resistency. Gut 2006, 55(Suppl V):A123.
35. ® cost-effective?. Dig Liv Dis 2007, 39:617-625.
36. Férnandez Pérez F.J., Rodríguez F., de Sola C., et al. Granulocytapheresis in inflammatory bowel disease. Efficacy of an induction plus maintenance sessions protocol at 32 weeks. Rev Esp Enferm Dig 2007, 11:628-635.
37. D'Ovidio V.D., Aratari A., Viscido A., et al. Mucosal features and granulocyte-monocyte apheresis in steroid-dependent/refractory ulcerative colitis. Dig Liver Dis 2006, 38:389-394.
38. Maiden L., Takeuchi K., Baur R., et al. Selective white cells apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008, 14:1413-1418.
39. Cuadrado E., Alonso M., de Juan M.D., et al. Regulatory T cells in patients with inflammatory bowel diseases treated with Adacolumn granulocytapheresis. World J Gastroenterol 2008, 14:1521-1527.
40. Muratov V., Lundhal J., Ufgren A.K., et al. Down-regulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006, 21:493-504.